

Review

Open Access

The function of APC/C^{Cdh1} in cell cycle and beyond

Min Li¹ and Pumin Zhang*^{1,2}

Address: ¹Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX 77030, USA and ²Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA

Email: Min Li - mli@bcm.edu; Pumin Zhang* - pzhang@bcm.edu

* Corresponding author

Published: 19 January 2009

Received: 6 January 2009

Cell Division 2009, **4**:2 doi:10.1186/1747-1028-4-2

Accepted: 19 January 2009

This article is available from: <http://www.celldiv.com/content/4/1/2>

© 2009 Li and Zhang; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The anaphase promoting complex/cyclosome (APC/C) is a multi-subunit E3 ubiquitin ligase playing essential functions in mitosis. It is conserved from yeast to human and relies on two adaptor proteins, Cdc20 and Cdh1, to bring in substrates. Both APC^{Cdc20} and APC^{Cdh1} are implicated in the control of mitosis through mediating ubiquitination and degradation of important mitotic regulators such as cyclin B1, securin, and Plk1. In addition, APC^{Cdh1} is thought to prevent premature S phase entry by limiting the accumulation of mitotic cyclins in G1 and to regulate processes unrelated to cell cycle. In this review, we will summarize our current understanding of APC^{Cdh1} function in cell cycle and beyond.

Introduction

Two ubiquitin E3-ligase complexes, SCF (Skp1/CUL1/F-box protein) and APC/C (anaphase promoting complex/cyclosome), control the timely transitions of cell cycle phases by promoting the degradation of many key cell cycle regulators. SCF complex mainly functions in G1, S and early M phases, whereas APC/C regulates mitosis including metaphase-anaphase transition and mitotic exit and maintains G1 phase [1,2]. APC/C is a large (1.5 MDa complex) composed of at least 11 core subunits. It relies on two WD-40 repeat-containing adaptor proteins, Cdc20/fizzy(fzy)/p53CDC and Hct1/srw1/fizzy-related(fzr)/Cdh1, to engage with its substrates. Destruction box (RxxLxxxxN/D/E) and KEN box are motifs frequently found in APC's substrates, but other motifs are also possible for recognition by APC^{Cdc20} or APC^{Cdh1} [3]. The consensus sequence of destruction box can be found in many proteins. However, not all of these proteins are APC's substrates. Thus, there must be other sequence constraints we do not understand yet that define true APC substrates. Moreover, some substrates only have an RxxL

motif and yet are recognized by APC, indicating the last amino acid in the consensus is not stringently conserved.

APC^{Cdc20} initiates the metaphase-anaphase transition through mediating the ubiquitination and degradation of cyclin B1 and securin. To prevent premature separation of sister chromatids and mitotic exit, APC^{Cdc20} is inhibited by Mad2 and BubR1 through the spindle assembly checkpoint mechanism [4-9]. Only when the sister chromatids are aligned at the metaphase plate and have established bivalent spindle attachment can the inhibition of APC/Cdc20 be released. In contrast to APC^{Cdc20}, APC^{Cdh1} is inactive in early mitosis [3] when it is inhibited by phosphorylation [10] and binding of Nup90/Rae1 complex [11,12]. APC^{Cdh1} only becomes active from late mitosis to G1. The difference in the timing of activation between APC^{Cdc20} and APC^{Cdh1} suggests a functional division between the two E3 ubiquitin ligases in mitosis. Recent analyses of mice deficient in Cdc20 or Cdh1 strongly support that notion [13-15]. It appears that Cdc20 is required for metaphase to anaphase transition [15], whereas Cdh1

plays a nonessential role in mitotic exit but an essential role in G1/S regulation [13,14].

Mitotic Function of Cdh1

A large number of mitotic regulators are degraded at the end of mitosis. These include Cdc20, Aurora B, Plk1, etc. and are most likely the substrates of APC^{Cdh1} (Table 1) [16-43]. Although many of these mitotic regulators did accumulate in the absence of Cdh1, they were eventually degraded, probably because of the stabilization of Cdc20 that compensates for the loss of Cdh1 [13,14]. As a result, Cdh1-deficient cells could still proliferate. However, these cells did accumulate mitotic errors and display difficulties in completing cytokinesis, resulting in the formation of binucleated cells at a high frequency [13,14].

The lethality associated with the loss of Cdh1 is largely a result of failed development of placenta, an essential organ for embryonic life in mammals [13,14]. In the placenta, there is a special cell type, giant cells which are polyploid. The polyploidy is acquired through endoreplication. In the absence of Cdh1, the placental giant cells failed to form, suggesting that APC^{Cdh1} is required for DNA endoreplication. To undergo endoreplication, a cell must not enter mitosis after a round of DNA synthesis. One critical factor for mitotic entry is cyclin B1, a substrate of APC^{Cdh1} [33]. Therefore, it is possible that the failed formation of giant cells in Cdh1 mutant embryos was a result of the inability of the would-be giant cells to block the accumulation of cyclin B1. Indeed, cyclin B1 was readily detectable in the mutant placenta in the area where the giant cells should reside [14].

Table 1: Substrates of APC^{Cdh1}.

Substrates	Function	Reference
Cdc20	anaphase onset	[16,17]
Securin	anaphase onset	[18,19]
Sgo1	anaphase onset	[20]
Rcs1	anaphase onset	[21]
XKid	spindle assembly	[22,23]
Tpx2	spindle assembly	[24]
Ase1	spindle assembly	[25,26]
Aurora A	mitotic exit	[27,28]
Aurora B	mitotic exit	[29]
Plk1	mitotic exit	[30]
Anillin	mitotic exit	[31]
CKAP2	mitotic exit	[32]
Cyclin B1	mitotic exit	[33]
Cyclin A	mitotic exit	[34]
Cdc6	DNA synthesis	[35-37]
Geminin	DNA synthesis	[38,39]
FoxM1	G1/G0 maintenance	[40,41]
SnoN	Tgf- β signaling	[42,43]
Ets2	Ras signaling	[77]
Id2	transcription	[86]

Like an endoreplicating cell, cells with their DNA damaged do not enter mitosis either. A recent study revealed that APC^{Cdh1}-mediated degradation of Plk1 played an important role in preventing mitotic entry of DNA-damaged cells [44]. Under normal conditions, Cdh1 is kept inactive from late G1 to early mitosis. When cells suffered DNA damage, Cdc14B is translocated out of nucleoli into nuclearplasm where the phosphatase dephosphorylates and activates Cdh1 [44]. It is unknown if a similar mechanism is employed by the placental giant cells to activate Cdh1 in G2 to prevent mitotic entry.

Maintenance of G1 by APC^{Cdh1}

In *Drosophila*, loss of *fzr* leads to an extra division cycle in the epidermis, a likely result of the accumulation of mitotic cyclins in G1 [45]. In HeLa cells, knocking down the expression of Cdh1 causes stabilization of Skp2 [46,47], a F-box containing protein responsible for bringing p27^{Kip1} to the SCF complex for ubiquitination [48,49]. As a result, p27 is destabilized in the cells with impaired Cdh1 function and the G1 phase is shortened in these cells.

Our recent work identified Ets2 as a new substrate of APC^{Cdh1} [14]. Ets2 is a member of the Ets family of transcription factors which share a unique DNA binding domain, the ETS domain [50,51]. The first Ets protein was identified as transduced mutant form of Ets1, v-Ets, in a retrovirus, E26 (E₂₆ twenty six-specific, so the name Ets) avian leukosis virus (ALV), that induces erythroblastosis in avian species [52]. It is well known that Ets2 is activated by Ras-Raf-MAPK signaling and mediates some effects of this important signaling pathway [53-59]. The most prominent effect of Ras signaling is the stimulation of proliferation which relies in part on the induction of cyclin D1 expression by Est2 [60,61]. Increased expression of Ets2 has been associated with initiation and progression of various cancer types [62-65] and its expression was altered in cervical cancer cell lines due to chromosomal changes in 21q22.1-22.2 where human ETS2 resides [66]. Moreover, Ets2 was found overexpressed in esophageal squamous cell carcinoma [67]. These results suggest that Ets2 is an oncogene. By targeting both Skp2 and Ets2, APC^{Cdh1} maintains G1 by increasing the levels of a Cdk inhibitor p27 through destabilizing Skp2 and by limiting the expression of cyclin D1 through promoting Ets2 degradation (Fig. 1). Since both Skp2 and Ets2 are potential oncogenes, APC^{Cdh1} may possess tumor-suppression activity. Indeed, mice heterozygous for Cdh1 display increased rates of tumorigenesis at old ages [13].

It was shown previously by Nasmyth's group that inactivation of APC/C by deleting its subunit APC2 in adult hepatocytes induced these otherwise quiescent cells to re-enter cell cycle [68]. This is most likely a result of the loss




Figure 1
Cdh1 regulate the timing of S-phase entry.

of APC^{Cdh1} activity and subsequent accumulation of Skp2 and Ets2.

To enter S-phase, APC^{Cdh1} must be inactivated. Several different mechanisms are in place to contain APC^{Cdh1} [69,70]. First, the ubiquitination of APC-specific ubiquitin-conjugating enzyme (E2) UbcH10 by APC^{Cdh1} itself provides a negative feedback mechanism that would eventually destroy APC^{Cdh1} activity [71,72]. Second, as Cdk activity accumulates, Cdh1 is phosphorylated. The phosphorylation promotes Cdh1 dissociation from APC [10,73]. Third, phosphorylated Cdh1 is targeted by SCF ligase [74], further limiting the activity of APC^{Cdh1}. Finally, in late G1 phase, E2F activates the transcription of early mitotic inhibitor-1 (Emi1)/Rca1, which inhibits the activity of APC/C^{Cdh1} as a pseudo-substrate [75,76].

Cdh1 and Cellular Senescence

Opposite to the expected high proliferation rates in Cdh1-deficient cells, Cdh1^{-/-} mouse embryonic fibroblasts (MEFs) proliferate poorly and entered senescence after only a few passages [77]. We found that the induction of p16^{Ink4a} in these cells was the cause for the reduced proliferation potential. The reason for the increased levels of p16 in Cdh1^{-/-} MEFs could simply be that p16 is a substrate of APC^{Cdh1}. Alternatively, it could be that a transcriptional activator of p16 is a substrate. It turned out that the latter was the case [14]. We demonstrated that


Cdh1-deficiency induced upregulation of p16 was a result of Ets2 stabilization. It was shown previously that Ets2 could activate p16 expression [78]. The expression of p16 is regulated by a number of factors in response to various stimuli. Under normal conditions, Ets2 levels are not enough to induce p16 expression and senescence because of Id1 and Bim1 (Fig. 2A). Id1 interacts with Ets2 and blocks its transcriptional activation of p16 [78,79], whereas Bmi1 directly represses p16 promoter [80]. Our identification of the APC^{Cdh1}-Ets2-p16 axis shows the delicacy of the balance that determines the level of p16 expression. Loss of Cdh1 leads to increases in the levels of Ets2 to the point that it overcomes Id1's inhibition and results in senescence (Fig. 2B). This would imply that Ets2 activity required for p16 activation and that for other targets are different, which remains to be determined.

Overactivation of Ras signaling could also cause senescence in primary cells [81-83]. It is likely that Ets2 mediates, at least in part, this senescence effect of Ras signaling (Fig. 2C). It remains to be determined however if Ras signaling interacts with APC^{Cdh1}. The phosphorylation of Ets2 by Erk may interfere with the recognition of Ets2 by Cdh1, for example, leading to stabilization of Ets2. Therefore, when Ras signaling is overactivated, APC^{Cdh1} would only be able to provide limited balancing function against Ets2. By placing p16 under the transcriptional control of Ets2, evolution has setup a failsafe mechanism to prevent unwarranted proliferation.

Cdh1 and Neural Function

Two places where appreciable levels of Cdh1 (and APC subunits) but not Cdc20 are expressed in adult mice are the brain and the liver [84]. In the liver, APC^{Cdh1} is likely required for preventing hepatocytes from reentering the cell cycle spontaneously (see above). What is the function of APC^{Cdh1} in postmitotic neurons? The depletion of Cdh1 expression in primary neuron of the cerebellar cortex promotes significant elongations of axons, indicating a role of APC^{Cdh1} in limiting axonal growth [85], possibly through regulating the abundance of SnoN and Id2 [86,87]. APC^{Cdh1} may also control patterning of axon growth in the mammalian brain [85].

We assessed neural functioning of mice that are heterozygous Cdh1 mutant. Electrophysiology studies of hippocampus revealed a deficit in late phase long-term potentiation (L-LTP), a process that underlies synaptic plasticity and is known to depend on both protein synthesis and degradation [88]. In behavior tests, we found that Cdh1 heterozygous mice performed poorly in contextual fear conditioning [14], a hippocampus-dependent process [89,90], but no difference was observed in cued fear condition which is less dependent on hippocampus [89,90]. Similar behavior findings were also reported by

**Figure 2**

Cdh1 and cellular senescence. (A) Under normal conditions, the expression of p16 is tightly controlled by both positive and negative regulators. (B) Deletion of Cdh1 causes accumulation of Est2, leading to overexpression of p16 and senescence. (C) Oncogenic Ras may also induce senescence through Ets2.

Malumbres' group [13]. It is unclear at the moment what are the substrates of APC^{Cdh1} that play a role in memory formation in mammals. However, studies from lower organisms may provide a clue. In *C. elegans*, the abundance of GLR-1 glutamate receptors in the ventral nerve cord is regulated by anaphase promoting complex, albeit unlikely to be in a direct manner [91]. In *Drosophila*, Liprin- α , a multidomain scaffolding protein which is localized to synapses and regulates synaptic activities, seems to be a substrate of APC^{Cdh1} [92]. It remains to be determined if mammalian homologues of Liprin- α and GLR-1 are regulated by APC^{Cdh1} and if their misregulation can account for the learning and memory defects displayed by Cdh1 heterozygous mice.

Conclusion

Tremendous progresses have been made towards understanding the regulation and function of APC/C in the last decade. Its role in cell cycle regulation has largely been elucidated. It appears that APC^{Cdc20} is dedicated to mitosis while APC^{Cdh1} has a much broader application not restricted to the cell cycle. The most intriguing question remains to be addressed is the role of APC/C in non-dividing cells. Accumulating evidence points to the involve-

ment of APC^{Cdh1} in many aspects of neural function including axon growth, morphology and plasticity of synapses, and learning and memory. Identification of the relevant substrates will provide significant insights into the functioning of the complex nervous system. Further, in addition to its potential role in maintaining the G0 state of hepatocytes, whether APC^{Cdh1} participates in the physiological function of the liver remains to be elucidated

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ML and PZ wrote the manuscript together.

Acknowledgements

This work was supported by grants from The National Institute of Health to PZ (CA122623-02 and CA116097-04). ML is supported by a NIH post-doctoral training grant.

References

1. Vodermaier HC: **APC/C and SCF: Controlling Each Other and the Cell Cycle.** *Curr Biol* 2004, **14**(18):R787-R796.
2. Nakayama KI, Nakayama K: **Ubiquitin ligases: cell-cycle control and cancer.** *Nature Reviews Cancer* 2006, **6**:369-381.

3. Harper JW, Burton JL, Solomon MJ: **The anaphase-promoting complex: it's not just for mitosis any more.** *Genes & development* 2002, **16(17)**:2179-2206.
4. Hwang LH, Lau LF, Smith DL, Mistrot CA, Hardwick KG, Hwang ES, Amon A, Murray AW: **Budding yeast Cdc20: a target of the spindle checkpoint.** *Science (New York, NY)* 1998, **279(5353)**:1041-1044.
5. Fang G, Yu H, Kirschner MW: **The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation.** *Genes & development* 1998, **12(12)**:1871-1883.
6. Kallio M, Weinstein J, Daum JR, Burke DJ, Gorbsky GJ: **Mammalian p55CDC mediates association of the spindle checkpoint protein Mad2 with the cyclosome/anaphase-promoting complex, and is involved in regulating anaphase onset and late mitotic events.** *J Cell Biol* 1998, **141(6)**:1393-1406.
7. Wu H, Lan Z, Li W, Wu S, Weinstein J, Sakamoto KM, Dai W: **p55CDC/hCDC20 is associated with BUBR1 and may be a downstream target of the spindle checkpoint kinase.** *Oncogene* 2000, **19(40)**:4557-4562.
8. Fang G: **Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit anaphase-promoting complex.** *Molecular biology of the cell* 2002, **13(3)**:755-766.
9. Tang Z, Bharadwaj R, Li B, Yu H: **Mad2-Independent inhibition of APCCdc20 by the mitotic checkpoint protein BubR1.** *Dev Cell* 2001, **1(2)**:227-237.
10. Kramer ER, Scheuringer N, Podtelejnikov AV, Mann M, Peters JM: **Mitotic regulation of the APC activator proteins CDC20 and CDH1.** *Molecular biology of the cell* 2000, **11(5)**:1555-1569.
11. Jeganathan KB, Baker DJ, van Deursen JM: **Securin associates with APCCdh1 in prometaphase but its destruction is delayed by Rael and Nup98 until the metaphase/anaphase transition.** *Cell Cycle* 2006, **5(4)**:366-370.
12. Jeganathan KB, Malureanu L, van Deursen JM: **The Rael-Nup98 complex prevents aneuploidy by inhibiting securin degradation.** *Nature* 2005, **438(7070)**:1036-1039.
13. García-Higuera I, Manchado E, Dubus P, Cañamero M, Méndez J, Moreno S, Malumbres M: **Genomic stability and tumour suppression by the APC/C cofactor Cdh1.** *Nature cell biology* 2008, **10(7)**:802-811.
14. Li M, Shin Y-H, Hou L, Huang X, Wei Z, Klann E, Zhang P: **The adaptor protein of the anaphase promoting complex Cdh1 is essential in maintaining replicative lifespan and in learning and memory.** *Nature cell biology* 2008, **10(9)**:1083-1089.
15. Li M, York JP, Zhang P: **Loss of Cdc20 causes a securin-dependent metaphase arrest in two-cell mouse embryos.** *Molecular and cellular biology* 2007, **27(9)**:3481-3488.
16. Prinz S, Hwang ES, Visintin R, Amon A: **The regulation of Cdc20 proteolysis reveals a role for the APC components Cdc23 and Cdc27 during S phase and early mitosis.** *Curr Biol* 1998, **8(13)**:750-760.
17. Pflieger CM, Kirschner MW: **The KEN box: an APC recognition signal distinct from the D box targeted by Cdh1.** *Genes & Development* 2000, **14**:655-665.
18. Zur A, Brandeis M: **Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis.** *The EMBO journal* 2001, **20**:792-801.
19. Zou H, McGarry TJ, Bernal T, Kirschner MW: **Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis.** *Science (New York, NY)* 1999, **285(5426)**:418-422.
20. Karamysheva Z, Diaz-Martinez L, Crow SE, Li B, Yu H: **Multiple APC/C degrons mediate the degradation of human SGO1.** *Journal of Biological Chemistry* 2008 in press.
21. Zhao W-m, Coppinger JA, Seki A, Cheng X-I, JRY III, Fang G: **RCS1, a substrate of APC/C, controls the metaphase to anaphase transition.** *The Proceedings of the National Academy of Sciences* 2008, **105(36)**:13415-13420.
22. Antonio C, Ferby I, Wilhelm H, Jones M, Karsenti E, Nebreda AR, Vernos I: **Xkid, a Chromokinesin Required for Chromosome Alignment on the Metaphase Plate.** *Cell* 2000, **102**:425-435.
23. Funabiki H, Murray AW: **The Xenopus Chromokinesin Xkid Is Essential for Metaphase Chromosome Alignment and Must Be Degraded to Allow Anaphase Chromosome Movement.** *Cell* 2000, **102**:411-424.
24. Stewart S, Fang G: **Destruction box-dependent degradation of aurora B is mediated by the anaphase-promoting complex/cyclosome and Cdh1.** *Cancer research* 2005, **65(19)**:8730-8735.
25. Juang Y-L, Huang J, Peters J-M, McLaughlin ME, Tai C-Y, Pellman D: **APC-Mediated Proteolysis of Ase1 and the Morphogenesis of the Mitotic Spindle.** *Science (New York, NY)* 1997, **275**:1311-1314.
26. Visintin R, Prinz S, Amon A: **CDC20 and CDH1: a family of substrate-specific activators of APC- dependent proteolysis.** *Science* 1997, **278(5337)**:460-463.
27. Castro A, Vigneron S, Bernis C, Labbe J-C, Prigent C, Lorca T: **The D-Box-activating domain (DAD) is a new proteolysis signal that stimulates the silent D-Box sequence of Aurora-A.** *EMBO Reports* 2002, **3**:1209-1214.
28. Castro A, Arlot-Bonnemains Y, Vigneron S, Labbé J-C, Prigent C, Lorca T: **APC/Fizzy-Related targets Aurora-A kinase for proteolysis.** *EMBO Reports* 2002, **3**:457-462.
29. Stewart S, Fang G: **Anaphase-Promoting Complex/Cyclosome Controls the Stability of TPX2 during Mitotic Exit.** *Molecular and cellular biology* 2005, **25(23)**:10516-10527.
30. Lindon C, Pines J: **Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells.** *J Cell Biol* 2004, **164(2)**:233-241.
31. Zhao W-m, Fang G: **Anillin Is a Substrate of Anaphase-promoting Complex/Cyclosome (APC/C) That Controls Spatial Contractility of Myosin during Late Cytokinesis.** *The Journal of biological chemistry* 2005, **280(39)**:33516-33524.
32. Seki A, Fang G: **CKAP2 is a spindle-associated protein degraded by APC/C-CDH1 during mitotic exit.** *The Journal of biological chemistry* 2007, **282(20)**:15103-15113.
33. King RW, Peters J-M, Tugendreich S, Rolfe M, Hieter P, Kirschner MW: **A 20s complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B.** *Cell* 1995, **81**:279-288.
34. Geley S, Kramer E, Gieffers C, Gannon J, Peters J-M, Hunt T: **Anaphase-promoting Complex/Cyclosome-dependent Proteolysis of Human Cyclin A Starts at the Beginning of Mitosis and Is Not Subject to the Spindle Assembly Checkpoint.** *The Journal of cell biology* 2001, **153**:137-148.
35. Duursma A, Agami R: **p53-Dependent Regulation of Cdc6 Protein Stability Controls Cellular Proliferation.** *Molecular and cellular biology* 2005, **25(16)**:6937-6947.
36. Mailand N, Diffley JFX: **CDKs Promote DNA Replication Origin Licensing in Human Cells by Protecting Cdc6 from APC/C-Dependent Proteolysis.** *Cell* 2005, **122**:915-926.
37. Petersen BO, Wagener C, Marinoni F, Kramer ER, Melixetian M, Denchi EL, Gieffers C, Matteucci C, Peters J-M, Helin K: **Cell cycle- and cell growth-regulated proteolysis of mammalian CDC6 is dependent on APC-CDH1.** *Genes & Development* 2000, **14**:2330-2343.
38. McGarry TJ, Kirschner MW: **Geminin, an Inhibitor of DNA Replication, Is Degraded during Mitosis.** *Cell* 1998, **93(6)**:1043-1053.
39. Zielke N, Querings S, Rottig C, Lehner C, Sprenger F: **The anaphase-promoting complex/cyclosome (APC/C) is required for rereplication control in endoreplication cycles.** *Genes & Development* 2008, **22**:1690-1703.
40. Park HJ, Costa RH, Lau LF, Tyner AL, Raychaudhuri P: **Anaphase-Promoting Complex/Cyclosome-Cdh1-Mediated Proteolysis of the Forkhead Box M1 Transcription Factor Is Critical for Regulated Entry into S Phase.** *Molecular and cellular biology* 2008, **28(17)**:5162-5171.
41. Laoukili J, Alvarez-Fernandez M, Stahl M, Medema RH: **FoxM1 is degraded at mitotic exit in a Cdh1-dependent manner.** *Cell Cycle* 2008, **7(17)**:2720-2726.
42. Wan Y, Liu X, Kirschner MW: **The anaphase-promoting complex mediates TGF-beta signaling by targeting SnoN for destruction.** *Mol Cell* 2001, **8(5)**:1027-1039.
43. Stroschein SL, Bonni S, Wrana JL, Luo K: **Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN.** *Genes & Development* 2001, **15**:2822-2836.
44. Bassermann F, Frescas D, Guardavaccaro D, Busino L, Peschiaroli A, Pagano M: **The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint.** *Cell* 2008, **134(2)**:256-267.

45. Sigrist SJ, Lehner CF: **Drosophila fizzy-related down-regulates mitotic cyclins and is required for cell proliferation arrest and entry into endocycles.** *Cell* 1997, **90(4)**:671-681.
46. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M: **Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase.** *Nature* 2004, **428(6979)**:190-193.
47. Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW, Kaelin WG Jr: **Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex.** *Nature* 2004, **428(6979)**:194-198.
48. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H: **p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27.** *Curr Biol* 1999, **9(12)**:661-664.
49. Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, Shirane M, Tsunematsu R, Tsukiyama T, Ishida N, et al: **Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication.** *The EMBO journal* 2000, **19(9)**:2069-2081.
50. Macleod K, Leprince D, Stehelin D: **The ets gene family.** *Trends in biochemical sciences* 1992, **17(7)**:251-256.
51. Crepieux P, Coll J, Stehelin D: **The Ets family of proteins: weak modulators of gene expression in quest for transcriptional partners.** *Critical reviews in oncogenesis* 1994, **5(6)**:615-638.
52. Leprince D, Gegonne A, Coll J, de Taisne C, Schneeberger A, Lagrou C, Stehelin D: **A putative second cell-derived oncogene of the avian leukaemia retrovirus E26.** *Nature* 1983, **306(5941)**:395-397.
53. Foulds CE, Nelson ML, Blaszcak AG, Graves BJ: **Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment.** *Molecular and cellular biology* 2004, **24(24)**:10954-10964.
54. Langer SJ, Bortner DM, Roussel MF, Sherr CJ, Ostrowski MC: **Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression.** *Molecular and cellular biology* 1992, **12(12)**:5355-5362.
55. Galang CK, Der CJ, Hauser CA: **Oncogenic Ras can induce transcriptional activation through a variety of promoter elements, including tandem c-Ets-2 binding sites.** *Oncogene* 1994, **9(10)**:2913-2921.
56. Yang BS, Hauser CA, Henkel G, Colman MS, Van Beveren C, Stacey KJ, Hume DA, Maki RA, Ostrowski MC: **Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2.** *Molecular and cellular biology* 1996, **16(2)**:538-547.
57. McCarthy SA, Chen D, Yang BS, Garcia Ramirez JJ, Cherwinski H, Chen XR, Klagsbrun M, Hauser CA, Ostrowski MC, McMahon M: **Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1.** *Mol Cell Biol* 1997, **17(5)**:2401-2412.
58. Wasyluk C, Bradford AP, Gutierrez-Hartmann A, Wasyluk B: **Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2.** *Oncogene* 1997, **14(8)**:899-913.
59. Patton SE, Martin ML, Nelsen LL, Fang X, Mills GB, Bast RC Jr, Ostrowski MC: **Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines.** *Cancer research* 1998, **58(10)**:2253-2259.
60. Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, Pestell RG: **Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions.** *The Journal of biological chemistry* 1995, **270(40)**:23589-23597.
61. Carbone GM, Napoli S, Valentini A, Cavalli F, Watson DK, Catapano CV: **Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells.** *Nucleic Acids Res* 2004, **32(14)**:4358-4367.
62. de Nigris F, Mega T, Berger N, Barone MV, Santoro M, Viglietto G, Verde P, Fusco A: **Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation.** *Cancer research* 2001, **61(5)**:2267-2275.
63. Neznanov N, Man AK, Yamamoto H, Hauser CA, Cardiff RD, Oshima RG: **A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice.** *Cancer research* 1999, **59(17)**:4242-4246.
64. Sapi E, Flick MB, Rodov S, Kacinski BM: **Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells.** *Cancer research* 1998, **58(5)**:1027-1033.
65. Sementchenko VI, Schweinfest CW, Papas TS, Watson DK: **ETS2 function is required to maintain the transformed state of human prostate cancer cells.** *Oncogene* 1998, **17(22)**:2883-2888.
66. Simpson S, Woodworth CD, DiPaolo JA: **Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines.** *Oncogene* 1997, **14(18)**:2149-2157.
67. Li X, Lu JY, Zhao LQ, Wang XQ, Liu GL, Liu Z, Zhou CN, Wu M, Liu ZH: **Overexpression of ETS2 in human esophageal squamous cell carcinoma.** *World J Gastroenterol* 2003, **9(2)**:205-208.
68. Wirth KG, Ricci R, Giménez-Abián JF, Taghybeeglu S, Kudo NR, Jochum W, Vasseur-Cognet M, Nasmyth K: **Loss of the anaphase-promoting complex in quiescent cells causes unscheduled hepatocyte proliferation.** *Genes & Development* 2004, **18**:88-98.
69. Peters J-M: **The anaphase promoting complex/cyclosome: a machine designed to destroy.** *Nature Reviews Molecular Cell Biology* 2006, **7**:644-656.
70. Pesin JA, Orr-Weaver TL: **Regulation of APC/C Activators in Mitosis and Meiosis.** *Annual Review of Cell and Developmental Biology* 2008, **24**:475-499.
71. Rape M, Kirschner MW: **Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry.** *Nature* 2004, **432**:588-595.
72. Rape M, Reddy SK, Kirschner MW: **The Processivity of Multiubiquitination by the APC Determines the Order of Substrate Degradation.** *Cell* 2006, **124(1)**:89-103.
73. Lukas C, Sørensen CS, Kramer E, Santoni-Rugiu E, Lindene C, Peters J-M, Bartek J, Lukas J: **Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex.** *Nature* 1999, **401**:815-818.
74. Benmaamar R, Pagano M: **Involvement of the SCF Complex in the Control of Cdh1 Degradation in S-phase.** *Cell Cycle* 2005, **4(9)**:1230-1232.
75. Hsu JY, Reimann JDR, Sørensen CS, Lukas J, Jackson PK: **E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APCCdh1.** *Nature cell biology* 2002, **4**:358-366.
76. Grosskortenhaus R, Sprenger F: **Rca1 Inhibits APC-Cdh1Fzr and Is Required to Prevent Cyclin Degradation in G2.** *Developmental Cell* 2002, **2(1)**:29-40.
77. Li M, Shin YH, Hou L, Huang X, Wei Z, Klann E, Zhang P: **The adaptor protein of the anaphase promoting complex Cdh1 is essential in maintaining replicative lifespan and in learning and memory.** *Nature cell biology* 2008, **10**:1083-1089.
78. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G, Hara E: **Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence.** *Nature* 2001, **409(6823)**:1067-1070.
79. Alani RM, Young AZ, Shifflett CB: **Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a.** *Proceedings of the National Academy of Sciences of the United States of America* 2001, **98(14)**:7812-7816.
80. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M: **Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.** *Genes Dev* 1999, **13(20)**:2678-2690.
81. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW: **Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.** *Cell* 1997, **88(5)**:593-602.
82. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW: **Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling.** *Genes Dev* 1998, **12(19)**:3008-3019.
83. Zhu J, Woods D, McMahon M, Bishop JM: **Senescence of human fibroblasts induced by oncogenic Raf.** *Genes Dev* 1998, **12(19)**:2997-3007.
84. Gieffers C, Peters BH, Kramer ER, Dotti CG, Peters JM: **Expression of the CDH1-associated form of the anaphase-promoting complex in postmitotic neurons.** *Proceedings of the National Acad-*

- emy of Sciences of the United States of America 1999, **96(20)**:11317-11322.
85. Konishi Y, Stegmüller J, Matsuda T, Bonni S, Bonni A: **Cdh1-APC Controls Axonal Growth and Patterning in the Mammalian Brain.** *Science (New York, NY)* 2004, **303**:1026-1030.
 86. Lasorella A, Stegmüller J, Guardavaccaro D, Liu G, Carro MS, Rothschild G, de la Torre-Ubieta L, Pagano M, Bonni A, Iavarone A: **Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth.** *Nature* 2006, **442(7101)**:471-474.
 87. Stegmüller J, Konishi Y, Huynh MA, Yuan Z, DiBacco S, Bonni A: **Cell-Intrinsic Regulation of Axonal Morphogenesis by the Cdh1-APC Target SnoN.** *Neuron* 2006, **50(3)**:389-400.
 88. Fonseca R, Vabulas RM, Hartl FU, Bonhoeffer T, Nagerl UV: **A balance of protein synthesis and proteasome-dependent degradation determines the maintenance of LTP.** *Neuron* 2006, **52(2)**:239-245.
 89. Kim JJ, Fanselow MS: **Modality-specific retrograde amnesia of fear.** *Science* 1992, **256(5057)**:675-677.
 90. Phillips RG, LeDoux JE: **Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.** *Behavioral neuroscience* 1992, **106(2)**:274-285.
 91. Juo P, Kaplan JM: **The Anaphase-Promoting Complex Regulates the Abundance of GLR-1 Glutamate Receptors in the Ventral Nerve Cord of *C. elegans*.** *Curr Biol* 2004, **14(22)**:2057-2062.
 92. Roessel Pv, Elliott DA, Robinson IM, Prokop A, Brand AH: **Independent Regulation of Synaptic Size and Activity by the Anaphase-Promoting Complex.** *Cell* 2004, **119(5)**:707-718.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

